The world’s hardest natural material also has the most enthralling sparkle – these two properties mean that tiny diamonds are giving us dramatic new ways of interacting with the human body.
Whether it’s enabling MRI scanners to see the way drugs move into cells, or creating durable connections between retinal implants and neurons, diamonds or even tiny fragments of them known as nanodiamonds are lending their glitter to medical research.
‘Diamonds or graphene are very dense materials and therefore nothing diffuses through their surfaces, so there is no contamination of such implants when used to electrically exchange with neural cells,’ said Professor Philippe Bergonzo, coordinator of the NEUROCARE project, which has developed a new type of interface linking medical devices to neural tissues like the retina or the brain based on nanocrystalline diamond and graphene.
‘The implant needs to be very close to neural tissues to make the difference between two nearby neurons,’ said Prof. Bergonzo, based at France’s Alternative Energies and Atomic Energy Commission. ‘In the NEUROCARE project … we were demonstrating that the graphene or diamond materials are able to reduce the tissue reaction, thus to be closer to the neuron cells in order to have a better-quality electrical interface that lasts longer.’
The work they are doing means that nanodiamond- and graphene-based brain interfaces are so durable that they could form the basis for long-lasting brain implants that can prevent epileptic fits, and so small that they can be connected directly to a neuron, making retinal implants good enough to allow blind people to read. While the EU is spending billions funding research and innovation, it often falls behind the US when it comes to turning those new ideas into commercial products. US-based venture capital firms are often willing to take on bigger risks than their European counterparts, which has led to the success of regions like Silicon Valley in California, home to Facebook, Google and Amazon. Carlos Moedas, European Commissioner for Research, Science and Innovation, has named open innovation the first priority of his tenure. He is exploring how a European Innovation Council could help inventors to commercialise their products, and looking at the possibility of a fund of funds to leverage more European venture capital.
While the EU is spending billions funding research and innovation, it often falls behind the US when it comes to turning those new ideas into commercial products.
US-based venture capital firms are often willing to take on bigger risks than their European counterparts, which has led to the success of regions like Silicon Valley in California, home to Facebook, Google and Amazon.
Carlos Moedas, European Commissioner for Research, Science and Innovation, has named open innovation the first priority of his tenure. He is exploring how a European Innovation Council could help inventors to commercialise their products, and looking at the possibility of a fund of funds to leverage more European venture capital.
Today’s experimental brain interfaces use metals such as platinum, but the problem in the long term is the potential degradation of the metal surface within the body, altering the electrical exchange.
That’s why nanodiamond technology is so important. It’s the kind of breakthrough that could one day lead to long-term help for locked-in patients, where experimental temporary brain implants aim at enabling them to communicate directly with computers and even operate exoskeletons in institutions such as the Clinatec institute at the Centre Hospitalier Universitaire Grenoble Alpes in France.
Now the NEUROCARE researchers are looking for a company with the cash to fund formal trials and try to get regulatory approval for it to be used in commercial products, a process which can take around five years.
This search has led them to look across the Atlantic, even though the original research was funded here in Europe.
‘In the US companies are a lot more ready to take risks,’ said Prof. Bergonzo. ‘It’s pretty difficult to find those ambitions in Europe nowadays.’
Innovative companies will also be key to bringing nanodiamond-based medical imaging technology out of the laboratory and into hospitals and clinics.
The NDI project, funded by the EU's European Research Council, is working on a way to use nanodiamonds to enable standard MRI scanners to zoom in on single cells. The project, which runs until the summer, has set up a company to develop the technology and is already collaborating with big high-tech firms such as Germany’s Bosch and France-based Thales.
‘Once big industry and small startups get involved in this, it will ensure the transfer of technology towards real-world applications,’ said coordinator Professor Fedor Jelezko, from Ulm University in Germany.
The technology means that cancer could be detected faster and would help increase the speed of drug development.
It’s all thanks to the unique properties of nanodiamonds, which are often made by milling down standard diamonds.
MRI scanners work by picking up the spin of atoms. However, normally they only pick one nucleus up out of a hundred thousand. ‘Diamond is a unique material.’ Professor Fedor Jelezko, Ulm University, Germany
‘Diamond is a unique material.’
Professor Fedor Jelezko, Ulm University, Germany
The way to improve this is to make the spins extremely cold, which is impossible in a live person.
In diamonds, the spin of carbon atoms can be controlled by light, and it can be made very cold using laser irradiation, which lasts for days.
‘To make the spins very cold, without cooling the sample, the body, we do it with light,’ Prof. Jelezko said. ‘That’s something where diamond is a unique material.’
The next step is to take the resolution further, and to make the technology user-friendly enough that it can be used in a live setting in medical laboratories.
‘There is a long way to go, but we and other colleagues are working on a path towards this dream,’ he said.
Nearly 100 years ago scientists developed a vaccine for tuberculosis (TB). Today, there are 10 million new cases worldwide and 1.6 million deaths from the disease every year. Increasingly, these cases are becoming difficult to treat as the bug that causes the disease can be resistant to antibiotics. However, several new TB vaccines are under development and there is growing optimism that a new vaccine will emerge, says Helen McShane, professor of vaccinology at Oxford University, UK. This could save millions of lives, she said, but more work is needed to reassure the general public that vaccines are safe and effective.
When an outbreak strikes, speed is critical. Health workers must act quickly not only to contain and treat an emerging or re-emerging disease, but also to use this window to evaluate potential treatments and vaccines. And the challenge becomes even greater in sub-Saharan Africa when you’re trying to develop new approaches in the face of multiple emerging diseases.
Forests have a special magic for many of us. Steeped in folklore and fantasy, they are places for enchantments, mythical creatures and outlaws. But if they are to survive into the future, they may also need a helping hand from science.
Nature provides people with everything from food and water to timber, textiles, medicinal resources and pollination of crops. Now, a new approach aims to measure exactly what a specific ecosystem supplies in order to incentivise decision-makers and businesses to help combat biodiversity loss.
Tuberculosis is the most common cause of death from an infectious disease.
Computer modelling will also help optimise management techniques.
Entrepreneur Nicklas Bergman on the European Innovation Council.